Targeting STIM1 or SOCE may sensitize prostate and human osteosarcoma cells to cisplatin treatment and hepatocarcinoma to 5-fluorouracil treatment by increasing autophagy, and overexpression of STIM1 increased chemoresistance in cisplatin-resistant cells [51,52]. Here, STIM1 is linked to osteosarcoma.